Biosimilars Pathway Tangled in High Court’s Pending Healthcare Reform Case

Drug Industry Daily
A A
The FDA’s abbreviated biosimilars review pathway may be in jeopardy if the Supreme Court strikes down last year’s massive health reform law, an industry attorney says.

To View This Article:

Login

Subscribe To Drug Industry Daily